Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ixazomib citrate works in treating patients with
multiple myeloma that has returned after a period of improvement (relapsed) but is not
resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.